1. Scrip
  2. >>Business

Beam Therapeutics’ Base-Edited CAR-T Placed On Hold

Latest Off-The-Shelf Therapy To Be Delayed

 
• By Andrew McConaghie

Beam is the latest allogeneic CAR-T developer to face a regulatory hold-up, but other candidates using its pioneering base-editing technology are now progressing.

DNA bases
Beam is a pioneer of a more precise technique in which 'single-letter' editing of DNA and RNA is possible. • Source: Shutterstock

The US Food and Drug Administration has placed a hold on Beam Therapeutics’s preclinical candidate, BEAM-201. It is the latest in a string of off-the-shelf cell therapies to be placed on hold by the regulator, though competitors in the field are now progressing after clearing safety checks.

Beam, which specializes in the new base-editing technology for gene therapy, said on 1 August that the regulator had put...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Ionis’s Dawnzera Becomes First RNA-Targeted HAE Prevention Drug

 
• By Joseph Haas

Dawnzera joins CSL’s recently approved Andembry as new additions to the crowded hereditary angioedema prevention market. It is priced at $57k per dose, but labeling includes four- or eight-week options.

Gilead’s Kite Is Latest To Enter In Vivo CAR-T Space With Interius Buy

 
• By Alaric DeArment

The CAR-T specialist is spending $350m to acquire the private Philadelphia-based firm, which is developing in vivo CAR-Ts using lentiviral vectors.

Former Moderna Exec Launches Company Focused On mRNA Despite HHS Funding Cuts

 
• By David Wild

Emerging Company Profile: Axelyf raises $2.6m seed round for lipid nanoparticle delivery platform on heels of end to US federal support for mRNA vaccines.

Nicox Plots US Submission After Another Phase III Glaucoma Win

 
• By Kevin Grogan

The France-headquartered firm’s eye drop has demonstrated efficacy in a second pivotal trial.

More from Scrip

Former Moderna Exec Launches Company Focused On mRNA Despite HHS Funding Cuts

 
• By David Wild

Emerging Company Profile: Axelyf raises $2.6m seed round for lipid nanoparticle delivery platform on heels of end to US federal support for mRNA vaccines.

Nicox Plots US Submission After Another Phase III Glaucoma Win

 
• By Kevin Grogan

The France-headquartered firm’s eye drop has demonstrated efficacy in a second pivotal trial.

Rocket’s Warp Drive Back Online As FDA Lifts Danon Gene Therapy Hold

 
• By Alaric DeArment

The company took a prophylactic C3 inhibitor out of the immunomodulatory regimen used in its Phase II study of RP-A501, lowered the dose and adjusted its use of eculizumab.